February 25, 2026
Bispecific ADCs: are dual-target ‘AND-Gate’ designs the future of tumour selectivity?
Antibody-drug conjugates (ADCs) continue to evolve as one of the most promising approaches in targeted cancer therapy, yet the fundamental…